Nearly a million people, and one shared system meant to speed up dementia trials
What happened
On 8 October 2026 the Prime Minister announced a £48 million industry partnership for dementia research. The announcement came from 10 Downing Street, ahead of the Innovation Nation Summit. Inside that figure, the government is putting in £33 million through the Dame Barbara Windsor Dementia Goals programme. The rest comes from three partners: Bristol Myers Squibb, GSK and Gates Ventures. The money goes to something called The BARBARA Alliance. It is a UK-wide not-for-profit partnership. Government, industry, universities, charities and people who live with dementia are all part of it. Its main project is also called BARBARA. The plan is to build one co-ordinated platform that links UK health data, research and clinical trial work. At the moment those things sit in separate places, which makes research slower than it needs to be. Prime Minister Andy Burnham said: "Dementia is a devastatingly cruel disease, not only for those who live with it, but for the families who care for them." He added that he has "real hope that we can come together and do exactly that." Health and Social Care Secretary Yvette Cooper said: "This cruel disease has done so much damage to families across our country".
Why this matters
Nearly one million people in the UK live with dementia. Around one in two of us will be affected at some point in our lives - either as a person with dementia, as a carer, or both. The cost is large too. The government puts it at over £42 billion a year. Most of that is social care and unpaid care given by families. The NHS share is about £7 billion. The problem this announcement is aimed at is not a shortage of people willing to help. It is a bottleneck. Niranjan Bose, Managing Director for Health and Life Sciences at Gates Ventures, put it plainly: "Recruiting the right people, at the right time, remains one of the biggest bottlenecks". That is the gap. Trials need the right volunteers. Researchers often cannot find them quickly enough. So trials run slowly, and answers arrive later than they could have done. Ken Rhodes, Vice President of Neuroscience Research at Bristol Myers Squibb, said: "BARBARA will help the Alzheimer's field ask better questions and accelerate progress for patients in need."
What the evidence actually says
It is worth being clear about what this is, and what it is not. This is money for research infrastructure. It is not a new treatment, and it is not a cure. Nothing announced on 8 October changes what a doctor can prescribe tomorrow. What the evidence does show is that people want to take part. Hilary Evans-Newton CBE chairs the Dame Barbara Windsor Dementia Goals programme and is chief executive of Alzheimer's Research UK. Her survey found that over 90% of people affected by dementia would like to take part in research. She said: "We know that people affected by dementia want the opportunity to be part of the search for better treatments." Two other pieces sit alongside this. The first is the Health Data Research Service. Dementia is to be one of its first priorities. It is backed by up to £600 million from the government and the Wellcome Trust. The idea is to bring NHS and research data into one secure system that approved researchers can use. The second is diagnosis. UK Research and Innovation has an £80 million Dementia Challenge that will test nine technologies in the NHS, including faster MRI brain scans and remote memory and thinking assessments. The target is for 92% of people to be diagnosed within 18 weeks of referral. Today it is around 60%. And an honest caveat. The £48 million figure appears in the headline and summary of the government's announcement, but the body of that announcement itemises only the £33 million of government money. How much each of the three company partners is putting in has not been published. No timescales were given either. So treat the headline figure as the total being claimed, not as a published breakdown.
Qurexa perspective
We deliver prescriptions and groceries across Lincolnshire, and a good share of those deliveries go to households living with dementia - either the person themselves, or a husband, wife, son or daughter doing the caring. What we see is the quiet, practical side of all this. Repeat prescriptions that need to arrive on the same day each month, so a routine does not slip. Blister packs that make a confusing day simpler. A doorstep conversation that is sometimes the only one a carer has that morning. Research platforms matter. So does the ordinary business of getting the right medicine to the right door on the right day. If you care for someone at home, and collecting medicine is one more job you cannot fit in, that is a job you are allowed to hand over.
Practical advice
If you want to help with dementia research, there is a free service built for exactly that. It is called Join Dementia Research. It is run by the National Institute for Health and Care Research with Alzheimer's Research UK, Alzheimer's Society and Alzheimer Scotland. Any UK resident over 18 can sign up. You do not need a dementia diagnosis. You do not even need to have memory concerns, because studies need healthy volunteers for comparison too. You can also sign up on behalf of someone else if you have their consent, or lasting power of attorney. In Northern Ireland, consent on someone else's behalf is not accepted. Signing up does not commit you to anything. The service matches you to studies and tells you about them. Whether you take part is your choice, every single time. If you are worried about your own memory, or someone else's, the first step is a GP appointment rather than a research sign-up. Before you go, write down what you have noticed and roughly when it started. That short list helps more than you might expect. A diagnosis opens the door to support, benefits advice, treatment - and research. If you are caring for someone, ask your council for a carer's assessment. It is free, and you are entitled to one.
What to know
On 8 October 2026 the government announced a £48 million industry partnership for dementia research. That includes £33 million of government money through the Dame Barbara Windsor Dementia Goals programme, alongside funding from Bristol Myers Squibb, GSK and Gates Ventures. It supports The BARBARA Alliance and its BARBARA platform, which will link UK health data, research and clinical trial capabilities so researchers can find the right volunteers faster. Nearly one million people in the UK live with dementia, and around one in two of us will be affected in our lifetime. The annual cost is put at over £42 billion, with £7 billion of that falling on the NHS. Dementia will be one of the first priorities of the Health Data Research Service, backed by up to £600 million from the government and the Wellcome Trust. Separately, UK Research and Innovation's £80 million Dementia Challenge is testing nine technologies in the NHS, with a target of 92% of people diagnosed within 18 weeks of referral, up from around 60% now. This is funding for research infrastructure, not a new medicine. Anyone over 18 in the UK can register free with Join Dementia Research, with or without a diagnosis. Sources: Prime Minister's Office, 10 Downing Street, "'I have real hope that Britain can come together to defeat dementia' - PM", 8 October 2026, https://www.gov.uk/government/news/i-have-real-hope-that-britain-can-come-together-to-defeat-dementia-pm ; Express & Star, "Andy Burnham unveils £48m partnership in bid to 'defeat' dementia", 8 October 2026, https://www.expressandstar.com/uk-news/andy-burnham-unveils-ps48m-partnership-in-bid-to-defeat-dementia-9276202 ; National Institute for Health and Care Research, "Join Dementia Research", accessed 9 October 2026, https://www.joindementiaresearch.nihr.ac.uk/ This article is for general information and does not replace advice from a doctor, pharmacist or other qualified healthcare professional.
Related articles
Six hours, not never: the ICU filter notice the MHRA issued today
The UK's medicines and devices regulator has issued a new safety notice to hospitals, and it is about timing. On 13 October 2026 the Medicines and Healthcare p…
Eight pages to a minister: what the data guardian says trust is worth
On 12 October 2026, the government published a letter about who should be trusted with NHS patient data. It was written by Dr Nicola Byrne, the National Data G…
Update: the tests came back, and it was not plague
This is a follow-up to a story we covered on 5 October, when nearly 200 people were being monitored after the death of a laboratory worker in Siberia. There has…